You are here

P&T March 2014


Health Plans and PBMs Would Be the Chief Beneficiaries
Medicare is proposing significant revisions to its Part D drug program. The biggest change: the elimination of antidepressants and immunosuppressants as “protected classes” on formularies in 2015 and the removal of antipsychotics in 2016.
A single-center retrospective study that compared clinical outcomes of patients with Legionella pneumonia treated with azithromycin versus fluoroquinolones for more than 12 years found that azithromycin appears to have clinical efficacy similar to fluoroquinolones.
Overexpression of human epidermal growth factor receptor 2 (HER2) is an important factor in cancer survival, proliferation, and metastasis. Agents that target HER2-positive tumors are used with traditional chemotherapies, with other targeted therapies, or as monotherapy to treat metastatic breast cancers.
P&T Snapshot

The American Cancer Society estimates that 40,000 women will die from breast cancer this year. But thanks to steady progress in the war on cancer, millions of U.S. women with a history of the disease are alive today. Key statistics on survival rates, therapies in use, and treatment costs are provided.


Medication Errors
Height and weight errors confound electronic prescribing.
Prescription: Washington
Drug makers and hospitals spar over shortage reporting.

Dapaglifozin (Farxiga) for improved glycemic control in type-2 diabetes, and trametinib (Mekinist) in combination with dabrafenib (Tafinlar) for the treatment of advanced, unresectable melanoma

FDA approvals, drug indications, and updates

Drug Forecast

Alogliptin (Nesina) for adults with type-2 diabetes